Immix Biopharma (NASDAQ:IMMX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immix Biopharma (NASDAQ:IMMX) from a sell rating to a hold rating in a report released on Saturday.

Several other analysts have also issued reports on IMMX. Mizuho started coverage on shares of Immix Biopharma in a research report on Monday, February 9th. They issued an “outperform” rating and a $14.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $15.00.

Immix Biopharma Trading Up 9.0%

Shares of Immix Biopharma stock opened at $10.13 on Friday. Immix Biopharma has a 1 year low of $1.34 and a 1 year high of $10.50. The company’s fifty day simple moving average is $6.48 and its 200-day simple moving average is $4.55. The company has a market cap of $536.48 million, a price-to-earnings ratio of -13.16 and a beta of 0.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IMMX. Imprint Wealth LLC acquired a new stake in Immix Biopharma during the third quarter worth $141,000. Quadrature Capital Ltd acquired a new position in shares of Immix Biopharma in the 4th quarter valued at $116,000. Squarepoint Ops LLC acquired a new position in shares of Immix Biopharma in the 4th quarter valued at $112,000. Tocqueville Asset Management L.P. lifted its holdings in shares of Immix Biopharma by 37.4% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after acquiring an additional 10,950 shares during the period. Finally, Velan Capital Investment Management LP lifted its holdings in shares of Immix Biopharma by 40.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock worth $73,000 after acquiring an additional 10,000 shares during the period. 11.26% of the stock is owned by institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.